×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Moneycontrol mutual fund summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Ads
Integration costs to continue into FY16: Sun Pharma
Sun will turn Ranbaxy profitable; stock fall brief: Angel
Ranbaxy effect playing on Sun Pharma's margins: Pros
Sun Pharma Q4 profit seen up 9.7%, sales may rise 16%: Poll
Sun Pharma maintains 13-15% FY15 topline guidance: CFO
Operating performance may hurt Sun Pharma's Q3 profit: Poll
Ranbaxy Q3 disappoints; US mkt, Diovan led to loss: Angel
Ranbaxy Labs Q3 revenue may rise 12% to Rs 3236 cr: Poll
Merger with Ranbaxy might get delayed: Sun CFO Baldota
US core business continues to be a drag for Ranbaxy: CIMB
Here's how experts read Ranbaxy's Q2FY15 earnings
Brokerages wary about Ranbaxy sustaining its performance
Healthy sales, operational growth push Ranbaxy 6% up: Angel
Key takeaways from Ranbaxy earnings commentary
Ranbaxy may post Q3 PAT at Rs 10 cr, guidance revision key
Ranbaxy Q3 net may rise 83.5% at Rs 112cr: Motilal Oswal
What you can expect from Ranbaxy in Oct-Dec quarter
Pharma companies revenues to rise 12% in Q3: Anand Rathi
Ranbaxy to drag; buy DRL, Glenmark; neutral on Lupin: Rathi
Ranbaxy disappoints on lower OPM, net profit: Angel Broking
Ranbaxy Q2 PAT may dip 19% at Rs 166.3 cr: Motilal Oswal
Ranbaxy likely to post Q3 loss at Rs 25.9 cr: P Lilladher
Ranbaxy Labs Q1 net seen down 60.5% at Rs 150 cr: Emkay
Ranbaxy Labs Q1: MOST expects PAT to dip 39% at Rs 105.5 cr
Ranbaxy Labs Q1 net may dip 127% at Rs 159 cr: P Lilladher
View More
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio